DNA-based HIV Vaccine: Interim Phase I data

Interim data from a U.S. Phase I trial in 24 evaluable healthy volunteers showed that the vaccine was well tolerated. Also, the vaccine induced HIV-1-specific T cell immune responses in peripheral blo...